Unicycive Therapeutics, Inc. — Form 8-K Summary
Business Context and Reporting Period
Unicycive Therapeutics, Inc. filed a Form 8-K reporting the results of its Annual Meeting of Stockholders held on June 15, 2022. The report was signed and dated June 16, 2022. The company is a Delaware corporation whose common stock trades on Nasdaq under the symbol UNCY.
Annual Meeting Results
- Quorum: 10,001,560 shares of common stock were represented in person or by valid proxy.
- Director elections: Dr. Shalabh Gupta, Dr. Sandeep Laumas, Dr. John Ryan, and Dr. Brigitte Schiller were each elected to serve until the 2023 annual meeting or until their successors are elected and qualified.
- Auditor ratification: Stockholders ratified the appointment of Mayer Hoffman McCann P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2022.
| Director | For | Withhold | Abstain | Broker Non-Vote |
|---|---|---|---|---|
| Dr. Shalabh Gupta | 8,551,089 | 0 | 65,794 | 1,384,677 |
| Dr. Sandeep Laumas | 8,536,637 | 0 | 80,246 | 1,384,677 |
| Dr. John Ryan | 8,550,547 | 0 | 66,336 | 1,384,677 |
| Dr. Brigitte Schiller | 8,536,656 | 0 | 80,227 | 1,384,677 |
| Auditor Ratification | Votes |
|---|---|
| For | 9,713,585 |
| Against | 7,378 |
| Abstain | 280,597 |
| Broker Non-Vote | 0 |
Financial Metrics and Material Changes
This filing does not report revenue, profit or loss, cash flow, margins, debt, liquidity, financial guidance, or other operating metrics. It does not disclose a material change versus a prior comparable period.
Outlook, Risks, and Unusual Items
The filing contains no updated guidance, management outlook, risk discussion, contingencies, or unusual financial items. The principal reported developments are the election of four directors and approval of the independent auditor.
Investor Verification Items
- Verify the election terms and continuing service of all four directors.
- Confirm Mayer Hoffman McCann P.C.’s appointment for the fiscal year ending December 31, 2022.
- Review the company’s other SEC filings for current cash resources, financing needs, operating losses, clinical development status, and related risks, none of which are provided in this 8-K.